AlphAIAlphAI — Financial news for AI agents
minichart.com.sgSEP 51 min read$HROW

Harrow CFO Boll Adds Principal Accounting Officer Role After Pollard Exit – Minichart

Harrow, Inc. (HROW) announced Randall E. Pollard's departure as Chief Accounting Officer. Andrew R. Boll, the CFO, will also serve as principal accounting officer without additional compensation. No reason was given for Pollard's exit.

Original reporting
minichart.com.sg
Published Sep 5, 2026, 1:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 5, 2026, 1:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Harrow CFO Boll Adds Principal Accounting Officer Role After Pollard Exit – Minichart — source image
Source · minichart.com.sg
Decision brief

The 30-second read

$HROWNeutralLow
01

Why it matters

The change is a routine corporate action with limited immediate market impact.

02

Market read

Minor news; likely neutral price reaction.

03

What to watch

Potential future audit scrutiny or SEC attention on internal controls.

Relevance 7/10Novelty 5/10Timing: effective September 4, 2026

Background

Harrow, Inc. (NASDAQ:HROW) disclosed an executive restructuring after the chief accounting officer's exit.

Company-level read

Ticker impact

$HROWNeutralHigh confidence
Context

Harrow CFO Andrew R. Boll was appointed principal accounting officer after Randall Pollard's departure.

Expected impact

minimal short-term impact, potential slight volatility as investors assess control risk

Evidence & confidence

No compensation change and no new strategic direction; market typically reacts modestly to CFO role expansions.

Market effects

Sector

None significant; affects only Harrow's governance perception.

Regional

US market only, no broader regional effect.

Global

Limited to investors in Harrow.

Counterpoint

What could challenge this read

The role consolidation could signal deeper governance issues, potentially prompting a short bias.

Key entities

  • Executive
    Andrew R. Boll

    President and CFO, now also principal accounting officer.

  • Executive
    Randall E. Pollard

    Former chief accounting officer, departed effective Sep 4, 2026.

Read at source← All news

Related articles

AUG 21
$HROWMedAI 8/10

What's Going On With Harrow Stock Friday? - Harrow (NASDAQ:HROW)

Harrow Inc. (NASDAQ:HROW) reported positive results from a clinical study of its ocular anesthetic IHEEZO, showing significant pain reduction compared to a control. Analysts noted the findings support long-term growth and maintained an Outperform rating. HROW shares were down 1.33% at $41.50 on Friday.

benzinga.com2 min
AUG 20
$HROWMed

Harrow (HROW): Strong Product Momentum Meets A Steep H2 Revenue Target

Harrow Inc. (HROW) reported H1 2026 revenue of $115M, below expectations, but reaffirmed its full-year guidance of $350M-$365M. Key products IHEEZO, VEVYE, and TRIESENCE showed strong growth, but the company faces a steep H2 revenue target. Harrow also announced a pending deal for TYRVAYA, expected to add $30M in 2027 revenue. Adjusted EBITDA was negative $1.2M for the quarter, and the company has $83.9M in cash.

yahoo.com2 min
AUG 13
$HROWMed

Harrow Q2 Earnings Call Highlights

Harrow (NASDAQ:HROW) reported Q2 revenue of $15.6M for IHEEZO, with demand up to 65,477 units (+44% sequential, +34% YoY) but revenue lagging due to distributor sell-through of prior inventory. Management cited normalized channel inventory, ~25% higher net pricing effective July 1, gross margin 71%, and cash of $83.9M. Harrow also discussed BYOOVIZ launch, VEVYE PBM coverage, and a pending TYRVAYA acquisition.

yahoo.com6 min